WO2019040105A3 - Compounds, salts thereof and their use in the treatment of diseases - Google Patents

Compounds, salts thereof and their use in the treatment of diseases Download PDF

Info

Publication number
WO2019040105A3
WO2019040105A3 PCT/US2018/000352 US2018000352W WO2019040105A3 WO 2019040105 A3 WO2019040105 A3 WO 2019040105A3 US 2018000352 W US2018000352 W US 2018000352W WO 2019040105 A3 WO2019040105 A3 WO 2019040105A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
compounds
salts
treatment
formula
Prior art date
Application number
PCT/US2018/000352
Other languages
French (fr)
Other versions
WO2019040105A2 (en
Inventor
Ethan S. Burstein
Roger Olsson
Karl Erik Jansson
Magnus Gustav Wilhelm BERGNER
Niklas Patrik SKÖLD
Henrik Von Wachenfeldt
Kyrylo POPOV
Oleksandr KOVALENKO
Per Tomas Klingstedt
Björn Gustav BORGSTRÖM
Larisa Yudina WAHLSTRÖM
Original Assignee
Acadia Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc. filed Critical Acadia Pharmaceuticals Inc.
Publication of WO2019040105A2 publication Critical patent/WO2019040105A2/en
Publication of WO2019040105A3 publication Critical patent/WO2019040105A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

The present disclosure relates to compounds according to Formula (I), treating diseases.
PCT/US2018/000352 2017-08-21 2018-08-20 Compounds, salts thereof and methods for treatment of diseases WO2019040105A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762548320P 2017-08-21 2017-08-21
US62/548,320 2017-08-21

Publications (2)

Publication Number Publication Date
WO2019040105A2 WO2019040105A2 (en) 2019-02-28
WO2019040105A3 true WO2019040105A3 (en) 2019-04-18

Family

ID=63794591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/000352 WO2019040105A2 (en) 2017-08-21 2018-08-20 Compounds, salts thereof and methods for treatment of diseases

Country Status (1)

Country Link
WO (1) WO2019040105A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111007184B (en) * 2019-12-30 2023-05-16 天津天士力圣特制药有限公司 Method for detecting content of 4-methylpiperazine-1-formyl chloride hydrochloride
CN113549006B (en) * 2020-04-26 2023-07-21 江苏恩华药业股份有限公司 Amide derivative and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110135A1 (en) * 2012-01-25 2013-08-01 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
WO2013110134A1 (en) * 2012-01-25 2013-08-01 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
WO2017018804A1 (en) * 2015-07-27 2017-02-02 주식회사 종근당 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707798A (en) 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110135A1 (en) * 2012-01-25 2013-08-01 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
WO2013110134A1 (en) * 2012-01-25 2013-08-01 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
WO2017018804A1 (en) * 2015-07-27 2017-02-02 주식회사 종근당 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEPAILLEUR, A. ET AL.: "Dual Histamine H3R/Serotonin 5-HT4R Ligands with Antiamnesic Properties: Pharmacophore-Based Virtual Screening and Polypharmacology", JOURNAL OF CHEMICAL INFORMATION AND MODELLING, vol. 54, 23 May 2014 (2014-05-23), pages 1774 - 1784, XP002787935, DOI: 10.1021/ci500157n *
RADHA CHARAN DASH, SHARAD H. BHOSALE*, SUHAS M. SHELKE, MUGDHA R. SURYAWANSHI AND KAKASAHEBR. MAHADIK: "Design, Synthesis, Pharmacological Evaluation and Descriptor BasedSimilarities Study of N,N-diphenyl-2-[4-(substituted phenyl)piperazin-1-yl]acetamides as Potential Antipsychotics", MEDICINAL CHEMISTRY, vol. 8, 14 May 2012 (2012-05-14), pages 1069 - 1075, XP002787934 *

Also Published As

Publication number Publication date
WO2019040105A2 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
MX2020001757A (en) Compounds, salts thereof and methods for treatment of diseases.
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MY197635A (en) Benzooxazole derivatives as immunomodulators
MX2017009571A (en) Heterocyclic itk inhibitors for treating inflammation and cancer.
MX2021001186A (en) Purinones as ubiquitin-specific protease 1 inhibitors.
SG11201901061QA (en) Heterocyclic compound
EA201891268A1 (en) COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS
MX2018000396A (en) Substituted aza compounds as irak-4 inhibitors.
NZ733174A (en) Quinazoline derivatives used to treat hiv
MX2015010125A (en) Pyridazinone-amides derivatives.
MX2021007268A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof.
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
EA201591743A8 (en) STIMULATORS sGC
PH12015502161A1 (en) Therapeutic compounds and compositions
EP4233910A3 (en) Methods of treatment of cholestatic diseases
MX2019005097A (en) Compositions and methods to treat citrus greening disease.
MX2017000524A (en) Novel substituted pyrimidine compounds.
MX2016006975A (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases.
MX2018006953A (en) Monomaleimide-functionalized platinum compounds for cancer therapy.
EA033446B1 (en) Heterocyclic compound for treating macular degeneration and/or stargardt&#39;s disease
MX2018005004A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof.
WO2019016597A3 (en) Synthetic proteins and therapeutic uses thereof
WO2019040105A3 (en) Compounds, salts thereof and their use in the treatment of diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18783158

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18783158

Country of ref document: EP

Kind code of ref document: A2